To include your compound in the COVID-19 Resource Center, submit it here.

Dexisometheptene mucate: Development discontinued

Tonix said it will discontinue development of TNX-201 after top-line data from a double-blind, U.S. Phase II trial in 147

Read the full 207 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE